Novo Nordisk Seeking to Expand Weight-Loss Drugs Access in Japan

Novo Nordisk A/S is seeking to broaden access to obesity treatments in Japan by targeting patients willing to pay out-of-pocket for GLP-1 drugs such as Wegovy.

The Danish drugmaker will work with physicians and patients on self-funded treatment pathways, Keisuke Kotani, the head of Novo’s Japan unit, said at a briefing in Tokyo Thursday. “There are many people who can’t access the treatment because of various reasons,” he said.